Dextromethorphan/Bupropion: First Approval
S. Keam
CNS Drugs October 27, 2022 DOI: 10.1007/s40263-022-00968-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Argues that dextromethorphan/bupropion received US approval in August 2022 for treating MDD in adults, summarizing the development milestones. |
Abstract
An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the antidepressant bupropion hydrochloride (an aminoketone and CYP2D6 inhibitor that increases dextromethorphan bioavailability) [AUVELITYTM; dextromethorphan/bupropion], is being developed by Axsome Therapeutics, Inc. for the treatment of major depressive disorder (MDD), Alzheimer’s disease agitation and smoking cessation. Dextromethorphan/bupropion was approved in the USA in August 2022 for the treatment of MDD in adults. This article summarizes the milestones in the development of dextromethorphan/bupropion leading to this first approval for the treatment of adults with MDD.
Citations in the library
Cited by 14
- Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms Neuropsychopharmacology July 24, 2023
- Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants Chemical Reviews November 30, 2023
- Clinical pharmacological innovation in the treatment of depression. Expert Review of Clinical Pharmacology April 1, 2023
- The Black Book of Psychotropic Dosing and Monitoring Psychopharmacology Bulletin August 12, 2025
- Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD). Advances in experimental medicine and biology 2024
and 9 more in the library
Cites 6
- Improvement in Anxiety Symptoms in Depressed Patients Treated With AXS-05 (DEXTROMETHORPHAN-BUPROPION): Results From the Evolve Open-Label, Long-Term Study CNS Spectrums April 1, 2023
- AXS-05 (DEXTROMETHORPHAN-BUPROPION) Improves Depressive Symptoms and Functioning in Patients With One Prior Treatment Failure: Results From the Evolve Long-Term, Open Label Study CNS Spectrums April 1, 2023
- Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). The Journal of Clinical Psychiatry May 30, 2022
- Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. American Journal of Psychiatry May 18, 2022
- Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs May 1, 2021
and 1 more in the library